BIOTEC: Biotec Pharmacon: Enters into UK distribution agreement for Woulgan with H&R Healthcare
10:32
(Tromsø, 20 August 2015) Biotec Pharmacon ASA (Biotec, OSE: BIOTEC) has
entered into a Woulgan distribution agreement with leading UK distributor H&R
Healthcare Ltd (H&R Healthcare, H&R). The agreement represents a milestone
in the strategy of securing strong regional business partners for Woulgan.
- Biotec is pleased to announce H&R Healthcare as our partner in the UK and
Ireland for the distribution of Woulgan. H&R is a leading distributor of
specialized wound care products and we look forward working closely with them to
introduce Woulgan in the important UK market, the second largest in Europe.
This agreement represents a milestone in our strategy of entering into
agreements with strong regional business partners to secure the full commercial
potential of Woulgan, says Svein Lien, CEO of Biotec Pharmacon.
Woulgan is a primary dressing for use on skin wounds, of which diabetic ulcer
treatment is the initial targeted market for this product. More than one in 20
people in the UK have diabetes and the illness is causing 100 amputations each
week. Studies and evaluations of Woulgan document significantly improved
healing during the treatment period, less pain and improved comfort compared to
other therapies.
- Woulgan will be an important and highly prioritized product for use in the
advanced wound care market. Our primary market segment will be within diabetes,
which is a large market in need of new products. We are looking forward to our
partnership with Biotec for this promising product, says Managing Director Mike
Hoskins in H&R Healthcare.
Biotec and H&R Healthcare will over the following 3 to 6 months period work
jointly to secure reimbursement for Woulgan in the high-end category of the
market. Biotec will support H&R Healthcare and expects limited costs to occur
prior to the introduction to the UK market. The agreement has an initial term of
3 years with automatic renewal thereafter unless terminated.
For additional information,
Svein Lien, CEO
+47 922 89 323
svein.lien@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops and manufactures novel
immunomodulating products, and has recently obtained CE-mark for Woulgan
containing its proprietary substance SBG. Woulgan is a primary dressing for
one-time use on skin wounds, including diabetic ulcers, bedsores, leg ulcers,
transplantation wounds, post-surgery wounds, trauma wounds, first- and second
-degree burns, abrasions, and cuts. ArcticZymes develops, produces and sells
enzymes of marine origin used in molecular DNA technologies and diagnostics,
growth markets where rapid technological developments are creating a strong
demand for new and improved enzymes.
About H&R Healthcare Ltd:
H&R Healthcare is a leading UK medical distribution company which represents
world-class companies in the product areas of Advanced Wound Management,
Compression, Infection Control and Skin Protection. In 2014, Aria Medical (a
subsidiary of H&R) was set up to distribute wound care products for leading
suppliers - Covidien, a Medtronic company and Mediq-Medeco. H&R have also
recently acquired CUI International - a manufacturer and developer of Ostomy and
Hernia support products.
Source Url: http://www.newsweb.no/index.jsp?messageId=383833
10:32
(Tromsø, 20 August 2015) Biotec Pharmacon ASA (Biotec, OSE: BIOTEC) has
entered into a Woulgan distribution agreement with leading UK distributor H&R
Healthcare Ltd (H&R Healthcare, H&R). The agreement represents a milestone
in the strategy of securing strong regional business partners for Woulgan.
- Biotec is pleased to announce H&R Healthcare as our partner in the UK and
Ireland for the distribution of Woulgan. H&R is a leading distributor of
specialized wound care products and we look forward working closely with them to
introduce Woulgan in the important UK market, the second largest in Europe.
This agreement represents a milestone in our strategy of entering into
agreements with strong regional business partners to secure the full commercial
potential of Woulgan, says Svein Lien, CEO of Biotec Pharmacon.
Woulgan is a primary dressing for use on skin wounds, of which diabetic ulcer
treatment is the initial targeted market for this product. More than one in 20
people in the UK have diabetes and the illness is causing 100 amputations each
week. Studies and evaluations of Woulgan document significantly improved
healing during the treatment period, less pain and improved comfort compared to
other therapies.
- Woulgan will be an important and highly prioritized product for use in the
advanced wound care market. Our primary market segment will be within diabetes,
which is a large market in need of new products. We are looking forward to our
partnership with Biotec for this promising product, says Managing Director Mike
Hoskins in H&R Healthcare.
Biotec and H&R Healthcare will over the following 3 to 6 months period work
jointly to secure reimbursement for Woulgan in the high-end category of the
market. Biotec will support H&R Healthcare and expects limited costs to occur
prior to the introduction to the UK market. The agreement has an initial term of
3 years with automatic renewal thereafter unless terminated.
For additional information,
Svein Lien, CEO
+47 922 89 323
svein.lien@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops and manufactures novel
immunomodulating products, and has recently obtained CE-mark for Woulgan
containing its proprietary substance SBG. Woulgan is a primary dressing for
one-time use on skin wounds, including diabetic ulcers, bedsores, leg ulcers,
transplantation wounds, post-surgery wounds, trauma wounds, first- and second
-degree burns, abrasions, and cuts. ArcticZymes develops, produces and sells
enzymes of marine origin used in molecular DNA technologies and diagnostics,
growth markets where rapid technological developments are creating a strong
demand for new and improved enzymes.
About H&R Healthcare Ltd:
H&R Healthcare is a leading UK medical distribution company which represents
world-class companies in the product areas of Advanced Wound Management,
Compression, Infection Control and Skin Protection. In 2014, Aria Medical (a
subsidiary of H&R) was set up to distribute wound care products for leading
suppliers - Covidien, a Medtronic company and Mediq-Medeco. H&R have also
recently acquired CUI International - a manufacturer and developer of Ostomy and
Hernia support products.
Source Url: http://www.newsweb.no/index.jsp?messageId=383833
Dette er en milepel i Biotec sin historie.
Nå venter vi på avtale i Tyskland/Norden og andre land i Europa. Det kan godt hende disse partnere man nå finner kan penetrere markedet vel så raskt som S/N ville vært i stand til. S/N bruker ofte lang tid på at snu seg rundt og et mindre selskap kan være mer hands on og til og med vel så godt inne med de forskjellige landene sin helsevesen. Hvilken pris kan aksjen få med England,Irland;Tyskland og Norden. Jeg vil si et sted mellom 20 og 35 kroner bør absolutt være mulig. Nå vil vi gjerne se flere avtaler og noen refusjonsgodkjenninger som vil dra kursen i riktig retning. Etter hvert blir det spennende og se hvor stort dette blir global sammenheng. Biotec Pharmacon kan vise seg å bli en vinner i et fallende børsmarked.
Nå venter vi på avtale i Tyskland/Norden og andre land i Europa. Det kan godt hende disse partnere man nå finner kan penetrere markedet vel så raskt som S/N ville vært i stand til. S/N bruker ofte lang tid på at snu seg rundt og et mindre selskap kan være mer hands on og til og med vel så godt inne med de forskjellige landene sin helsevesen. Hvilken pris kan aksjen få med England,Irland;Tyskland og Norden. Jeg vil si et sted mellom 20 og 35 kroner bør absolutt være mulig. Nå vil vi gjerne se flere avtaler og noen refusjonsgodkjenninger som vil dra kursen i riktig retning. Etter hvert blir det spennende og se hvor stort dette blir global sammenheng. Biotec Pharmacon kan vise seg å bli en vinner i et fallende børsmarked.
Da foreligger det et oppdatert kursmål på 21 kroner fra Carnegie med UK og Irland med en forventning at salget først kommer skikkelig i gang etter nyttår og at selskapet går i pluss i 2017. Dette er opp 2 kroner siden siste kursmål på 19 som var før avtalen i UK. Med Tyskland Norden og noen land til er vi vel snart nærmere 50 kroner. En av Oslo børs sine mest spennende aksjer. Dette er da strong buy på dagens kurser
Mange pasienter i UK og Irland kan glede seg se bildet under!
